Jim Clemmer, President, CEO, Director, AngioDynamics [NASDAQ:ANGO]
“I had my career, my wife, my daughter. It was as if life came to a standstill,” says John Neet, a Stage III pancreatic cancer patient.
Let’s rewind a little to understand the gravity of his words.
Neet was living life to its fullest. With a career in golf, he was enjoying the little things in life with his wife and daughter. All was going in his favor until 2015 when dark clouds replaced the lush green horizon. Accosted by terrible back pain and fatigue, Neet decided to visit a doctor. Much to his dismay, despite the multiple rounds at clinics, none could diagnose the precise illness behind his symptoms. “While some thought it might be Parkinson or Brain Tumor, others questioned me of my drinking or smoking habits,” says Neet.
It was around this time when his doctor-friend suggested Neet to go for a CAT scan. 20th May, 2016. The CAT scan results reported a 5cmtumor inside Neet’s pancreas. Unable to understand his next plan of action, Neet followed the advice of his peers and caregivers and went ahead with the treatment procedures of AngioDynamics.
Fast forward to today, Neet has not only defeated the disease but also identifies himself as an advocate of pancreatic cancer patients. In fact, he has been named the PGA Professional of the year and even won a golf tournament soon after his second procedure. All thanks to AngioDynamics.
At The Forefront of Medical Device Technology
AngioDynamics brings impeccable benefits to the table by focusing on developing disruptive and differentiated technologies that address unmet patient needs and support professional healthcare providers around the world in the delivery of high-quality patient care. The company understands the important responsibility it has in a patient’s care, and hence, adheres to the highest standards of quality and compliance in everything that it does. With its disruptive and innovative medical devices, AngioDynamics addresses unmet patient needs by elevating the standard of care for chronic and acute disease states in vascular, peripheral vascular, and oncology medicine.
A leading provider of minimally invasive medical devices used by professional healthcare providers for oncology, vascular access, surgery, and peripheral vascular disease, AngioDynamics is deeply committed to improving patient care by ethically serving its customers, shareholders, and employees. Since its founding in 1988, as a division of E-Z-EM, AngioDynamics has earned the medical community’s trust. With a sheer focus on developing innovative medical devices that address unmet patient needs, the company has emerged as a supporter of the medical community’s reliable partner over the years. In 2018, the FDA granted NanoKnife System a breakthrough device designation under the 21st Century Cures Act, followed by approving NanoKnife® Irreversible Electroporation “Direct IRECancer Treatment” clinical study (DIRECT) in 2019. The DIRECT Study supports a proposed expanded indication for the NanoKnife System in the treatment of Stage III pancreatic cancer. “The DIRECT study design demonstrates our commitment to provide an option that addresses a pressing unmet need for patients with Stage III pancreatic cancer,” says Jim Clemmer, President, Director and CEO of AngioDynamics. “We are confident that our comprehensive approach, crafted through a constructive dialogue with the FDA, will generate meaningful data for clinicians, patients, payors and other stakeholders who are equally committed to fighting this disease, and we are dedicated to the idea that the standard of care for this deadly disease can—and should—improve.”
The company banks on its rich history that’s deeply rooted in the heart of “Catheter Valley,” to become an industry-leading provider of high-quality medical devices used by physicians for the treatment of cancer and peripheral vascular disease around the world. Under its hood, it has a comprehensive suite of products like DuraMax® Chronic Dialysis Catheter, SmartPort+, C3 Wave* System, Xcela Plus Ports, Auryon, BioFlo Midline Catheter, among others to serve patients across various medical realms like oncology, venous therapies, vascular interventions, midlines, ablation, and others. To understand how AngioDynamics is moving the needle with its product portfolio, let us dig in deeper.
We are confident that our comprehensive approach, crafted through a constructive dialogue with the FDA, will generate meaningful data for clinicians, patients, payors and other stakeholders who are equally committed to fighting this disease
Today, AngioDynamics has become a leading and trusted partner in oncology patient care. Its strategic portfolio offers improved solutions to address each step of a patient’s cancer therapy journey. The company’s NanoKnife 3.0 System is pushing the boundaries of modern-day ablation through its unique Irreversible Electroporation (IRE) technology that does not rely on heat to achieve cell death. Instead, it uses a more natural method that destroys only targeted tissue, sparing critical structures including vessels, nerves and ducts; an enhanced user experience–streamlining procedure set up and delivering real-time visual feedback.
What makes NanoKnife 3.0 System indispensable among oncologists? The answer lies is the advanced Irreversible electroporation (IRE) technique that uses a non-thermal energy to create permanent nanopores in the cell membrane to disrupt cellular homeostasis. The disruption of cellular homeostasis initiates an apoptotic-like effect which leads to permanent cell death. After delivering a sufficient number of high voltage pulses, the cells within the electrical field will be irreversibly damaged. The highly natural method destroys only targeted tissue, sparing critical structures including vessels, nerves, and ducts, thereby reducing the chances of contamination spread.
With a portfolio featuring its Solero Microwave Ablation System and breakthrough NanoKnife System with irreversible electroporation (IRE) technology, the company’s Oncology group is pioneering alternative ablation techniques. Combined with its early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies, the AngioDynamics Oncology group offers medical professionals with disruptive, patient-focused technologies that deliver safer, clinically-relevant, economically-favorable solutions for patients.
Taking interventional performance to new heights, the AngioDynamics Mariner Hydrophilic-Coated Angiographic Catheters promotes smooth navigation, as the innovative coating technology reduces catheter surface friction by as much as 90 percent. An effective, safe and practical alternative to continuous infusion of therapeutic agents, the Pulse*Spray® infusion system by AngioDynamics supplies physicians with the tools they need to efficiently pulse the chosen therapeutic agent into the target vessel. With dual check valves and pressure response outlets allow for even distribution of fluid volume along the entire length of the clot, the Pulse*Spray infusion system can maximize the dispersion of the enzyme throughout the target occlusion, thereby reducing duration of treatment and minimizing the systematic effects of the therapeutic agent.
Another arm of its oncology solutions includes the UniBlate RFA electrode that is built-in a thermocouple and deployed linearly to provide full temperature feedback and RF control and eliminate the need to stock multiple electrodes for multiple ablation volumes. As the only thermal-based ablation system with a real-time tissue monitoring at the margin of the ablation, the AngioDynamics Radiofrequency Interstitial Tissue Ablation (RITA or RFA) is a minimally invasive procedure in which a thin needle electrode is inserted into an unresectable liver lesion under ultrasound or CT guidance. Leveraging data support that when used in conjunction with traditional chemotherapy and other modalities such as embolization and chemo-embolization, RITA/RFA bridges patients to transplant or extends patient survival when transplant is not an option.
Moving ahead, with a strong value proposition in place along with the commitment to excellence in healthcare, a bright future awaits AngioDynamics, which is focused on enhancing the quality of life for patients with cancer.